Co-optation of two new members of the Board of Directors, resignation of three Directors Milan, October 22, 2015 – Today the Board of Directors of MolMed S.p.A. (Milan: MLM) co-opted Dr. Riccardo Palmisano and Prof. Didier Trono as new members of the Board of Directors following the resignation from office, during the same meeting, of […]
MolMed NGR-hTNF ASCO 2015, oral presentation of survival data
Oral presentation at ASCO 2015 of survival data in poor prognosis patients achieved in the Phase III trial on NGR-hTNF treatment in pleural mesothelioma Milan (Italy), 1 June 2015 – MolMed S.p.A. (MLM.MI) announces that the complete results of the Phase III trial with its investigational therapeutic NGR-hTNF in mesothelioma were presented and discussed orally […]
MolMed NGRhTNF ASCO New Data Show Significantly Extended Survival
A statistically significant 40% improvement of both overall survival and progression-free survival in a large population of patients, identified by a pre-specified analysis on the prior treatment-free interval, and who presented a very dismal prognosis was reported by MolMed S.p.A. (MLM.MI) this weekend, at the 50th ASCO annual meeting. These efficacy results were observed in […]
MolMed TK ASCO new data from the pivotal Phase III randomized trial TK008
MolMed S.p.A. (MLM.MI) provided at the 50th ASCO annual meeting new data from the ongoing randomised pivotal Phase III study on its cell therapy product TK for high-risk acute leukaemia patients transplanted from partially matched (haplo-identical) donors. The intent-to-treat analysis of the first 24 patients treated with TK indicates a 74% 1-year disease free survival […]
MolMed reports top line results of NGR-hTNF in the phase III trial in malignant pleural mesothelioma
MolMed S.p.A. (MLM.MI) today announced the results of the double-blinded, placebo-controlled Phase III trial of NGR-hTNF versus best investigator choice in 400 patients with malignant pleural mesothelioma who had previously failed a first-line chemotherapy. Despite not meeting its primary endpoint of improving overall survival (OS) in the entire population, the study showed a […]
TK submission for Conditional Approval validated by EMA
MolMed S.p.A. (Milan:MLM) announces that the European Medicines Agency (EMA) has validated the submission of the Conditional Marketing Authorisation for TK, a novel proprietary investigational cell-gene therapy. The data review of the submitted dossier starts today. TK is an adjunctive treatment in hematopoietic stem cell transplantation for patients affected by high risk leukaemia. TK has […]
- 1
- 2
- 3
- …
- 5
- Next Page »